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Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis and is thought to be autoimmune in nature.
Recent studies have described genes that act as master controllers of autoimmunity. Protein tyrosine phosphatase type 22
(PTPN22) and Cytotoxic T lymphocyte antigen-4 (CTLA-4) are two of these genes, and single nucleotide polymorphisms
(SNPs) in the genes encoding these molecules have been associated with several autoimmune diseases. In this study we
have analyzed SNPs in PTPN22 and CTLA-4 in patients with AAU.
Methods: The functional protein tyrosine phosphatase type 22 (PTPN22) SNP (R620W rs2476601, 1858C/T), and two
CTLA-4 SNPs (rs5742909, −318C/T and rs231775, 49A/G) were analyzed in 140 patients with AAU and 92 healthy
controls by sequence-specific primer -polymerase chain reaction (SSP-PCR). Data was analyzed by χ2 analysis and
Fisher’s exact test.
Results: There was no significant association between PTPN22 620W, CTLA-4 −318C/T, or CTLA-4 49A/G and AAU.
Similarly, there was no association with the three SNPs when patients were classified by race or gender. Finally, there
was no association with the presence of ankylosing spondylitis in the patient cohort.
Conclusions: The data do not support an association between SNPs in PTPN22 and CTLA-4, genes regarded as genetic
master switches of autoimmunity. This raises the issue of the etiology of AAU and the possibility that it should be regarded
as an autoinflammatory rather than an autoimmune condition.
Uveitis or inflammation of the uvea is a significant cause
of  visual  loss.  Clinically,  uveitis  can  be  categorized  into
distinct  phenotypes.  Acute  anterior  uveitis  (AAU),  which
presents unilaterally with sudden onset, is self-limiting and
recurrent  and  represents  the  specific  uveitis  phenotype
associated  with  ankylosing  spondylitis  (AS)  and  other
seronegative  spondyloarthropathies  (SpA)  [1].  A  link
between AAU, AS, and SpA is the major histocompatability
complex (MHC) class I molecule, human leucocyte antigen
B-27 (HLA-B*27). Although the frequency of patients with
AAU who are positive for HLA-B*27 varies among different
published  surveys,  it  is  generally  estimated  that  among
Caucasian patients with AAU, 50% are positive for HLA-
B*27 [2].
It is clear that even in HLA-B27-associated AAU, other
genetic  factors  are  involved.  Several  functional
polymorphisms in genes that produce proteins relevant to the
immune response have been described to either confer an
altered susceptibility to autoimmune diseases or appear to
influence their severity and outcome. Identification of such
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polymorphisms is important as it may help to advise patients
on  prognosis  and  influence  the  choice  and  dose  of
immunosuppressive drugs, particularly biological agents [3,
4].
A functional single nucleotide polymorphism (SNP) of
the  gene  encoding  protein  tyrosine  phosphatase  type  22
(PTPN22; R620W rs2476601, 1858C/T) has recently been
described as a strong common genetic risk factor for human
autoimmune disease [5]. PTPN22 is located on chromosome
1p13.3 and encodes a lymphoid-specific phosphatase (Lyp)
that  binds  to  c-src  tyrosine  kinase  (Csk),  an  intracellular
tyrosine  kinase.  Csk  phosphorylates  leucocyte-specific
tyrosine kinase (Lck), leading to the inhibition of Lck kinase
activity.  The  PTPN22  R620W  mutation  leads  to  reduced
binding of Lyp to Csk, resulting in reduced Lck inactivation,
with the overall effect of a gain of function mutation. This is
associated  with  downregulation  of  early  T  cell  receptor
signaling that results in an increase in autoreactive T cells and
autoantibody  production,  a  process  thought  to  be  due  to
defective  deletion  of  autoreactive  T  cells  during  thymic
maturation or dysfunction of regulatory T cells [6]. PTPN22
R620W has been associated with rheumatoid arthritis, type 1
diabetes  mellitus,  systemic  lupus  erythematosus,  and
autoimmune thyroiditis. In contrast, PTPN22 R620W has not
been  associated  with  two  other  presumed  autoimmune
disorders, multiple sclerosis and Crohn’s disease [7,8].
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208Human Cytotoxic T lymphocyte antigen-4 (CTLA-4) is
located  on  chromosome  2p33,  and  two  well  studied
polymorphisms in this gene are −318 C to T, (rs5742909) and
−49 A to G (rs231775). In particular, the 49G polymorphism
has been linked to reduced expression of CTLA-4 on the T
cell  surface,  reduced  soluble  CTLA-4  production,  and
subsequently impaired inhibitory function [9]. The biological
importance of such a change is supported by the findings that
the 49 A/G SNP has been associated with Graves’ disease,
type 1 diabetes mellitus, primary biliary cirrhosis, and, in
combination  with  a  second  CTLA-4  SNP  6230  G/A,  an
increased rate of acute rejection in patients undergoing liver
transplantation  [10-12].  In  this  study,  PTPN22  R620W,
CTLA-4  −318C/T,  and  CTLA-4  49A/G  were  tested  for
association with disease in a cohort of patients with AAU.
Associations with race, gender, and presence of AS were also
tested.
METHODS
Subjects: One hundred and forty subjects with AAU were
recruited  through  Oregon  Health  and  Science  University,
Portland, OR. The diagnostic validation of AAU was based
on  an  ophthalmology  chart  review  by  J.R.S.  The  clinical
criteria  for  the  diagnosis  of  AAU  include  documented
evidence through an assessment by slit-lamp biomicroscopic
examination of anterior chamber inflammation that is sudden
in onset, unilateral, and resolves within 12 weeks. This form
of  uveitis  is  typically  episodic,  and  although  it  presents
unilaterally, it may flip-flop, involving the companion eye in
recurrence. Individuals were considered to be affected with
uveitis if (1) they met the AAU criteria after careful review of
ophthalmology chart notes or (2) they were referred to the
study by a uveitis specialist with first-hand knowledge of the
subjects’ uveitis presentation. Ninety-two race and gender
matched  healthy  individuals  were  used  as  controls.  This
research  was  conducted  under  human  subject  protocols
approved by the OHSU, the St. Thomas' Hospital, London and
the Sandwell and West Birmingham National health Service
Trust, Birmingham, UK local ethics committees and adhered
to the Declaration of Helsinki agreement.
Single  nucleotide  polymorphism  analysis:  After  informed
consent,  blood  samples  were  collected  by  venepuncture.
Genomic DNA was prepared using standard salt extraction
techniques  and  stored  at  –70  °C  until  use.  The  PTPN22
R620W, CTLA-4 −318C/T, and CTLA-4 +49A/G SNPs were
detected  by  sequence-specific  primer-polymerase  chain
reaction (SSP-PCR) using primer mixes (Table 1).
Statistics: Associations with disease were sought between
allele frequencies. χ2 analysis was performed using EpiStat
(EpiStat Group Inc, Atlanta GA). A case-control analysis was
employed using the Fisher’s exact test.
RESULTS
The AAU cohort consisted of 140 subjects (78 female, 62
male) with 133 identified Caucasian by self-report. Of the 140
with AAU, 76 were without history of AS while 58 had a
diagnosis and the remaining six subjects were considered to
have probable or early signs of AS. The healthy control cohort
represented 92 subjects (54 female, 38 male), 81 of whom
were Caucasian.
The minor allele frequencies of CTLA-4 −318 and +49
were 8.9% and 42.1%, respectively, in the AAU group, and
4.9%  and  36.4%,  respectively,  in  the  healthy  controls.
Although we noted slightly higher minor allele frequencies of
both  SNPs  in  the  AAU  group,  the  differences  were  not
statistically significant (Table 2). The SNP allele frequencies
in the control group were in agreement with other published
Caucasian cohorts [9]. Furthermore, sub-analyses with only
the Caucasian samples or only the subjects without AS or a
haplotype analysis of the two SNPs (Table 2) did not reveal
any significant differences between the cases and controls.
The PTPN22 R620W variant allele frequency was 9.8%
in the healthy control cohort, which was similar to a UK
control cohort and other published reports [7,13]. This was
higher than the variant allele frequency found in the AAU
group  (6.5%),  but  this  difference  was  not  statistically
significant (p=0.217; Table 3). By restricting the analysis to
Caucasian samples, the variant allele frequency was 11.1%
and  6.8%  in  controls  and  AAU  patients,  respectively
(p=0.151).  Furthermore,  sub-analysis  of  only  those  AAU
subjects without AS revealed no difference between controls
(9.8%) and cases (9.21%, p=1.000).
DISCUSSION
Acute anterior uveitis (AAU) is the most common form of
immune-mediated  uveitis  and  is  strongly  associated  with
HLA-B27 and spondyloarthritis. In this study, we sought to
determine if polymorphisms in genes encoding genetic master
TABLE 1. PCR PRIMER SEQUENCES AND LENGTH OF AMPLIFICATION PRODUCT.
Gene Allele Sequence 5′-3′ Control primer
CTLA4 −318C CACTTAGTTATCCAGATCCTC TGCCAAGTGGAGCACCCA A
−318T CACTTAGTTATCCAGATCCTT GCATCTTGCTCTGTGCAGAT
49A CAGGGCCAGGTCCTGGT
49G CAGGGCCAGGTCCTGGC Product 745 basepairs
Product 402 basepairs
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209switches,  PTPN22  and  CTLA-4,  contribute  to  AAU.  The
results show that neither PTPN22 R620W nor CTLA-4 SNPs
(−318, +49) are associated with AAU in this cohort. As the
PTPN22 620W frequency varies in different geographical
areas, we analyzed only the Caucasians in our cohort and again
found  no  significant  association.  Finally,  there  was  no
association between any of the polymorphisms tested and AS
in  the  patient  group.  These  data  show  that  PTPN22  and
CTLA-4 polymorphisms do not influence onset or severity of
AAU.
As stated, AAU has been strongly linked to HLA-B*27
and SpA. In recent studies, uveitis has been described as a first
symptom in nearly half of SpA patients [14]. AAU has also
been  associated  with  early  onset  of  SpA  in  HLA-B*27-
positive  patients  [15].  Conversely,  patients  with  an
extraocular disease have a greater number of uveitis relapses
compared to ocular disease alone. These studies involved
patients  at  tertiary  referral  centers.  By  comparison,  in  a
primary care setting, HLA-B*27, AS, or family history of AS
did not influence relapses in these patients whereas patients
with one relapse were more likely to have a second event
[16]. Therefore, HLA-B*27 appears to be involved with more
severe AAU.
AAU has been classified as an autoimmune condition.
However, the evidence to support this is lacking. Numerous
studies  have  shown  serum  antibodies  to  Gram  negative
bacteria,  including  Helicobacter  pylori,  Chlamydia
trachomatis,  Salmonella,  and  Proteus  sp,  in  HLA-B*27–
TABLE 2. ALLELE FREQUENCY AND GENOTYPE ANALYSIS OF CTLA-4 −318 AND +49 POLYMORPHISMS IN PATIENTS WITH AAU AND HEALTHY
CONTROLS.
AAU patients                                  Controls
     (n=140)                                         (n=92)                                           p value
CTLA-4 −318
C 0.91 0.95 0.14
T 0.09 0.05
Genotype
CC 123 83 ns
CT 15 9
TT 2 0
CTLA-4 +49
A 0.58 0.64 0.24
G 0.42 0.36
Genotype
AA 49 38 ns
AG 64 41
GG 27 13
CTLA-4 Haplotype
CA 138 108 0.06
CG 117 67 0.29
TA 25 9 0.15
TT 0 0 -
There was no significant differences in haplotype or genotype frequency between patients with AAU and healthy controls.
ns=not significant.
TABLE 3. ALLELE FREQUENCY AND GENOTYPE ANALYSIS OF PTPN22 620W POLYMORPHISM IN PATIENTS WITH AAU AND HEALTHY
CONTROLS.
PTPN22
AAU patients                                Controls 
   (n=140)                                         (n=92)                                          p value
Allele Frequency
C 0.93 0.90                                               0.2
T 0.07 0.10
Genotypes
CC 123 75 ns
CT 14 16
TT 2 1
There was no significant differences in haplotype or genotype frequency between patients with AAU and healthy controls.
ns=not significant.
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210positive and SpA patients. In particular, the response to H.
pylori was greater in patients compared to healthy controls,
although this may have been biased by the lack of HLA-B*27
in the control group [17]. Neutrophils and monocytes from
patients with active AAU have a decreased expression of Toll-
like receptor 2 (TLR2), and reduced cytokine production on
signaling through TLR4, which suggests a defect in response
to a microbial trigger, and a defect in response to pathogens
may be involved in AAU [18].
The lack of association between the SNPs of PTPN22 and
CTLA-4  and  AAU  does  not  support  dysfunction  in  the
adaptive immune response. Therefore, the possibility exists
that the defect is in the innate immune system and that AAU
is  autoinflammatory  rather  than  autoimmune.
Autoinflammation  is  described  as  local  factors  at  sites
predisposed to disease, leading to the activation of innate
immune cells including macrophages and neutrophils [19].
Recent  genetic  studies  endorse  such  a  scenario.
Polymorphisms in tumor necrosis factor (TNF; -308A and
-238A), which are associated with increased production of the
cytokine,  are  significantly  more  frequent  in  HLA-B*27–
positive patients [20]. Similarly, HLA-B*27–positive patients
with extraocular disease show an association with SNPs in the
TNFRSF1A gene (TNFR1) compared to patients with AAU
alone [21]. Interestingly, anti-TNF therapy has been shown to
decrease the number of anterior chamber cells rapidly, to
speed resolution of disease, and to reduce the rate of relapse
on follow-up [22,23]. A SNP in the gene encoding CCL-2
(−2518G),  which  is  associated  with  significantly  higher
production  of  a  chemokine  involved  in  monocyte  and
neutrophil migration, was significantly associated with HLA-
B*27–positive AAU [24]. Increased production and response
to  TNF  in  response  to  infection  and  exacerbated  by  the
presence  of  HLA-B*27  [25]  would  lead  to  endothelial
activation and increased chemokine expression in many sites
including the eye with the resultant influx of blood leucocytes,
the majority of which would not be ocular specific. The self-
limiting and relapsing nature of AAU could be explained by
these mechanisms
However, other genes are involved in AAU. A recent
whole genome SNP analysis comparing patients with AAU
and patients with AS identified a region of chromosome 9 that
was linked to AAU but not AS unlike most of the other
hotspots [26]. The specific genes involved are currently being
investigated.
CTLA-4  polymorphisms  have  been  reported  in  other
ocular diseases. Similar to the findings in the current study,
−318C/T and 49A/G were not significantly associated with
intermediate uveitis or Behcet’s disease [13]. Conversely, in
Chinese  patients  with  Vogt-Koyanagi-Harada  (VKH)
syndrome 49G, and a haplotype based on four CTLA-4 SNPs,
linked to reduced function, were associated with susceptibility
to the syndrome [27]. In patients with Fuch's heterochromic
cyclitis CTLA-4 -318T and a microsatellite repeat, linked to
increased function, were associated with disease [28]. These
differences may be explained by the nature of the disease type,
autoimmune  (VKH)  or  infectious  (FHC),  compared  to
idiopathic uveitis or possibly due to ethnic differences. These
aspects should be investigated in future studies.
There are caveats in our study. The SNPs tested are not
the only ones reported for these genes, and it remains possible
that other mutations may influence AAU. Similarly, other
genes including NOD2 and FOXP3 are regarded as master
switches of autoimmunity, and these genes were not included
in this study. In conclusion, the lack of association between
SNPs  in  the  genetic  master  switches  of  autoimmunity,
PTPN22 and CTLA-4, suggests that regardless of the strong
linkage  with  HLA-B*27,  AAU  should  be  regarded  as  an
autoinflammatory rather than an autoimmune condition.
ACKNOWLEDGMENTS
Supported by Research to Prevent Blindness awards to the
Casey Eye Institute, and Drs. Martin, Smith and Rosenbaum;
and  National  Institutes  of  Health  R01-EY-013139.  The
Birmingham Eye Foundation (G.R. Wallace). The authors
wish  to  thank  the  individuals  with  uveitis,  referring
physicians, and the Spondylitis Association of America for
their  cooperation.  We  appreciate  the  expert  assistance  of
Carrie  Austin,  Trudy  Doyle,  Kelley  Goodwin  and  Elli
Kondeatis in subject enrollment and technical help.
REFERENCES
1. Smith JR. HLA-B27 associated uveitis. Ophthalmol Clin North
Am 2002; 15:297-307. [PMID: 12434478]
2. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis
and HLA-B27. Surv Ophthalmol 2005; 50:364-88. [PMID:
15967191]
3. Gough  SC,  Walker  LS,  Sansom  DM.  CTLA4  gene
polymorphism  and  autoimmunity.  Immunol  Rev  2005;
204:102-15. [PMID: 15790353]
4. Rioux JD, Abbas AK. Paths to understanding the genetic basis
of  autoimmune  disease.  Nature  2005;  435:584-9.  [PMID:
15931210]
5. Bottini  N,  Musumeci  L,  Alonso  A,  Rahmouni  S,  Nika  K,
Rostamkhani  M,  MacMurray  J,  Meloni  GF,  Lucarelli  P,
Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A
functional  variant  of  lymphoid  tyrosine  phosphatase  is
associated with type 1 diabetes. Nat Genet 2004; 36:337-8.
[PMID: 15004560]
6. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari
P, Nika K, Tautz L, Tasken K, Cucca F, Mustelin T, Bottini
N. Autoimmune-associated lymphoid tyrosine phosphatase is
a  gain-of-function  variant.  Nat  Genet  2005;  37:1317-9.
[PMID: 16273109]
7. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22:
setting thresholds for autoimmunity. Semin Immunol 2006;
18:214-23. [PMID: 16731003]
8. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in
type  1  diabetes  and  other  autoimmune  disease.  Semin
Immunol 2006; 18:207-13. [PMID: 16697661]
Molecular Vision 2009; 15:208-212 <http://www.molvis.org/molvis/v15/a20> © 2009 Molecular Vision
2119. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML,
DeGroot LJ. CTLA-4 gene polymorphism at position 49 of
exon  1  reduces  the  inhibitory  function  of  CTLA-4  and
contributes to the pathogenesis of Graves’ disease. J Immunol
2000; 165:6606-11. [PMID: 11086105]
10. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R,
Herwig J, Usadel KH, Badenhoop K. CTLA-4 alanine-17
confers genetic susceptibility to Graves’ disease and type 1
diabetes mellitus. J Clin Endocrinol Metab 1997; 82:143-6.
[PMID: 8989248]
11. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce
S,  Bassendine  MF.  CTLA-4  gene  polymorphism  confers
susceptibility to primary biliary cirrhosis. J Hepatol 2000;
32:538-41. [PMID: 10782900]
12. Tapirdamaz O, Pravica V, Metsaelaar HJ, Hansen B, Moons L,
van Meurs JB, Hutchinson IV, Shaw J, Agarwal K, Adams
DH, Day CP, Kwekkeboom J. Polymorphisms in the T cell
regulatory gene cytotoxic T lymphocyte antigen 4 influence
the rate of acute rejection after liver transplantation. Gut 2006;
55:863-8. [PMID: 16299026]
13. Bye L, Modi N, Stanford MR, Kondeatis E, Vaughan R, Fortune
F, Kanawati C, Ben-Chetrit E, Ghabra M, Murray PI, Wallace
GR. CTLA-4 polymorphisms are not associated with ocular
inflammatory  disease.  Tissue  Antigens  2008;  72:49-53.
[PMID: 18498289]
14. Fernandez-Melon J, Muñoz-Fernández S, Hidalgo V, Bonilla-
Hernán G, Schlincker A, Fonseca A, Vieitez J, Martín-Mola
E. Uveitis as the initial clinical manifestation in patients with
spondyloarthropathies. J Rheumatol 2004; 31:524-7. [PMID:
14994399]
15. Sampaio-Barros PD, Conde RA, Bonfiglioli R, Bertolo MB,
Samara AM. Characterization and outcome of uveitis in 350
patients  with  spondyloarthropathies.  Rheumatol  Int  2006;
26:1143-6. [PMID: 16957887]
16. Natkunarajah M, Kaptoge S, Edelsten C. Risks of relapse in
patients with acute anterior uveitis. Br J Ophthalmol 2007;
91:330-4. [PMID: 17035277]
17. Otasevic  L,  Zlatanovic  G,  Stanojevic-Paovic  A,  Miljkovic-
Selimovic  B,  Dinic  M,  Djordjevic-Jocic  J,  Stankovic  A.
Helicobacter  pylori;  an  underestimated  factor  in  acute
anterior uveitis and spondyloarthopathies. Ophthalmologica
2007; 221:6-13. [PMID: 17183194]
18. Chang JH, Hampartzoumian T, Everett B, Lloyd A, McCluskey
PJ, Wakefield D. Changes in Toll-like receptor (TLR)-2 and
TLR4 expression and function, but not polymorphisms are
associated with acute anterior uveitis. Invest Ophthalmol Vis
Sci 2007; 48:1711-7. [PMID: 17389503]
19. McGonagle D, McDermott MF. A proposed classification of
the  immunological  diseases.  PLoS  Med  2006;  3:e297.
[PMID: 16942393]
20. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch
U,  Ulrich  S,  Ardjomand  N,  Hermann  J.  Polymorphisms
within the tumor necrosis factor-alpha promoter region in
patients with HLA-B27-associated uveitis: association with
susceptibility  and  clinical  manifestations.  Ophthalmology
2006; 113:695-700. [PMID: 16581430]
21. Kuo NW, Lympany PA, Menezo V, Lagan AL, John S, Yeo
TK, Liyanage S, du Bois RM, Welsh KI, Lightman S. TNF
−857T, a genetic risk marker for acute anterior uveitis. Invest
Ophthalmol Vis Sci 2005; 46:1565-71. [PMID: 15851552]
22. El-Shabrawi Y, Hermann J. Anti-tumour necrosis factor-alpha
therapy with infliximab as an alternative to corticosteroids in
the  treatment  of  human  leucocyte  antigen  B27-associated
acute  anterior  uveitis.  Ophthalmology  2002;  109:2342-6.
[PMID: 12466181]
23. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence
of anterior uveitis in patients with ankylosing spondylitis
treated with anti-tumor necrosis factor agents infliximab and
etanercept.  Arthritis  Rheum  2005;  52:2447-51.  [PMID:
16052578]
24. Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S,
Hermann J, Ardjomand N, Haller-Schober EM, El-Shabrawi
Y. Role of CCL2/MCP-1 −2518A>G gene polymorphism in
HLA-B-27 associated uveitis. Mol Vis 2005; 11:896-900.
[PMID: 16280979]
25. Bowness P. HLA-B27 in health and disease: a double-edged
sword. Rheumatology 2002; 41:857-68. [PMID: 12154202]
26. Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajska BM,
Coffman JE, Smith JR, Becker MD, Mackensen F, Khan MA,
Levinson RD, Schumacher HR, Wade NK, Rosenbaum JT,
Reveille JD. A locus on chromosome 9p predisposes to a
specific  disease  manifestation,  acute  anterior  uveitis,  in
ankylosing spondylitis, a genetically complex, multisystem,
inflammatory  disease.  Arthritis  Rheum  2005;  52:269-74.
[PMID: 15641041]
27. Du L, Yang P, Hou S, Lin X, Zhou H, Huang X, Wang L,
Kiljstra  A.  Association  of  the  CTLA-4  gene  with  Vogt-
Koyangi-Harada syndrome. Clin Immunol 2008; 127:43-8.
[PMID: 18282809]
28. Spriewald  BM,  Lefter  C,  Huber  I,  Lauer  B,  Wenkel  H.  A
suggestive association of Fuch’s heterochromic cyclitis with
cytotoxic T cell antigen 4 polymorphism. Ophthalmic Res
2007; 39:116-20. [PMID: 17287608]
Molecular Vision 2009; 15:208-212 <http://www.molvis.org/molvis/v15/a20> © 2009 Molecular Vision
The print version of this article was created on 20 January 2009. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
212